{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["6(3)"],"submitter":["Bolanos-Meade J"],"funding":["National Institute of Allergy and Infectious Diseases","U.S. Department of Health and Human Services","NHLBI NIH HHS","National Heart, Lung, and Blood Institute","National Cancer Institute","NCI NIH HHS","Health Resources and Services Administration"],"journal":["The Lancet. Haematology"],"pagination":["e132-e143"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6503965"],"repository":["biostudies-literature"],"pubmed_title":["Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)."],"pmcid":["PMC6503965"],"funding_grant_id":["P30 CA008748","U24-CA76518","UG1 HL069290","UG1 HL069291","HHSH234200637015C","UG1 HL109137","U24 HL138660","UG1 HL069310","U10 HL069294","UG1 HL108945","P01 CA049605","U10 HL069291","U24 CA076518","UG1 HL069315","UG1 HL069249"],"pubmed_authors":["Chen YB","Wu J","Jones RJ","Bickett K","MacMillan ML","Logan BR","Mielcarek M","Koreth J","Pidala J","Geller NL","Jacobsohn DA","Weisdorf DJ","Bolanos-Meade J","Horowitz MM","Porter DL","Giralt SA","Abhyankar S","Noel P","Fei M","Fraser R","Holtan SG","Reshef R","Efebera YA","Hari P","Sobecks R","Pasquini MC","Pusic I","Solomon SR","Damon LE","Arai S","Antin JH","Liesveld JL","Alousi AM","Al-Kadhimi Z"],"additional_accession":[]},"is_claimable":false,"name":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).","description":null,"dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-05-07T13:24:09.578Z","creation":"2025-04-06T18:53:25.822Z"},"accession":"S-EPMC6503965","cross_references":{"pubmed":["30824040"],"doi":["10.1016/s2352-3026(18)30221-7","10.1016/S2352-3026(18)30221-7"]}}